Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy

Annals of Surgical Oncology

Volumn 22, Issue 4, 2015, Pages 1385-1391

  Teoh, Jeremy Yuen Chun ^a   Tsu, James Hok Leung ^b   Yuen, Steffi Kar Kei ^b   Chan, Samson Yun Sang ^a   Chiu, Peter Ka Fung ^a   Lee, Wai Man ^a   Wong, Ka Wing ^b   Ho, Kwan Lun ^b   Hou, Simon See Ming ^a   Ng, Chi Fai ^a   Yiu, Ming Kwong ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SURVIVAL RATE; TIME TO THE PROSTATE SPECIFIC ANTIGEN NADIR; BLOOD; BONE NEOPLASMS; CANCER GRADING; FEMALE; MORTALITY; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SECONDARY; TIME;

AGED; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS;

EID: 84925538769     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4105-8     Document Type: Article

References (15)

1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol. 2002; 168:9–12.
2. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615–24.
3. Ablin RJ, Pfeiffer L, Gonder MJ, Soanes WA. Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate. Exp Med Surg. 1969;27:406–10.
4. Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC, Morales AR. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer. 1981;48:1229–32.
5. Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP. The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013;112:548–60.
6. Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN, Gnanapragasam VJ. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol. 2011;137:235–41.
7. Sasaki T, Onishi T, Hoshina A. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis. 2011;14:248–52.
8. Huang SP, Bao BY, Wu MT, et al. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate. 2011;71:1189–97.
9. Huang SP, Bao BY, Wu MT, et al. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. Aging Male. 2012;15:34–41.
10. Choueiri TK, Xie W, D’Amico AV, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009;115:981–7.
11. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer. 2004;108:877–81.
12. Benaim EA, Pace CM, Lam PM, Roehrborn CG. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology. 2002;59:73–8.
13. D’Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer. 2007;109:1290–5.
14. Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D’Amico AV. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology. 2008;71:136–40.
15. Kitagawa Y, Ueno S, Izumi K, Mizokami A, Hinotsu S, Akaza H, Namiki M. Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP). J Cancer Res Clin Oncol. 2014;140:673–9.